Kornimate/medical-research-clean huggingface dataset:
the effect of vitamin a supplementation on cytokine profile in obesity

Conditions: Obesity

Summary: in this double blind placebo controlled trial,cytokine secretion of cd4+ t-cells after 4 month supplementation of vitamin a will be compared with placebo intaking group.

obesity is a chronic disease consisting of the increase in body fat stores. obesity is an important health concern because of its well known relationships with metabolic and endocrine disorders such as cardiovascular disease, type 2 diabetes, hypertension and immune dysfunction. low-grade systemic inflammation, confirmed by the increase of inflammatory markers such as c-reactive protein and interleukin-6 has been observed in obesity. cd4+ t-helpers are the most important regulators of immune system. epidemiological evidence has linked obesity to several (but not all) autoimmune disorders, including inflammatory bowel disease (ibd) and psoriasis .some sublineages of t- helpers plays core roles in immune dysfunction, and recent evidence demonstrates that an imbalance of t-cell subgroups including th1, th2, th17 and treg has occurred in obesity. this imbalance is the redirection of the immune response from most often th2 and treg like responses to th1 and th17 like responses respectively, however the opposite is desired. vitamin a (va) or va-like analogs known as retinoids, are potent hormonal modifiers of type 1 or type 2 responses but a definitive description of their mechanism(s) of action is lacking. high level dietary vitamin a enhances th2 cytokine production and iga responses, and is likely to decrease th1 cytokine production. retinoic acid inhibits il-12 production in activated macrophages, and ra pretreatment of macrophages reduces ifnγ and tnf α production and increases il4 production in antigen primed cd4 t cells. supplemental treatment with vitamin a or retinoic acid (ra) decreases ifnγ and increases il5, il10, and il4 production.

Eligibility criteria:
inclusion criteria: waist to hip ratio \>0.8 and bmi\>30 kg/m2 for obese individuals waist to hip ratio \<0.8 and bmi 18.5 - 24.9 kg/m2 for non obese individuals exclusion criteria: * subjects who have diseases which affect on th1/th2 balance such as asthma, active viral infections, and autoimmune diseases, or * subjects with pregnancy, lactation, menopause, diabetes * subjects who have allergy to vitamin a compounds, or * subjects who have used vitamin supplements or in last 3 months, or * subjects with morbid obesity(bmi \>40 kg/m2),or * overweight subjects (25 \<bmi\<29.9 kg/m2)

Keywords: obesity vitamin a immune system
minimal stimulation protocol using aromek(letrozole) and follitrope(recfsh) combined with invocell-low cost ivf

Conditions: Primary Infertility; Secondary Infertility; Low Responders; Mild to Moderate Male Factor Infertility

Summary: the purpose of this study to evaluate a low cost minimal stimulation protocol combined with intravaginal culturing, to make ivf affordable and available across the large infertile/subfertile population

in routine art procedures for ivf, ovarian stimulation is performed using down regulation with gnrh agonist combined with high daily fsh doses followed with ovulation induction with hcg 10000 iu, ovum pick-up 34-36 hours after hcg injection and embryo transfer on day 2, 3 or 5. in routine art procedure for ivf, embryology is done in very high tech lab, contamination free environment, which also exclude voc, high quality co2 incubators, laminar flow with heated table top, high magnification stereo microscope along with equipments for maintaining quality control, with a highly trained embryologist. the primary reason is we need to create a womb like environment in the embryology lab as eggs, and mainly fertilised embryos are going to spend minimum 2 or 3 and in case blastocyst 5 days in this lab. in recent years, various studies have been published identifying various minimal stimulation protocols for ivf, and also another variation of ivf where rather than using co2 incubator for culturing, vaginal cavity of the female partner is used for incubation using a specially designed capsule which have walls permeable to vaginal pco2 and o2. oocytes are retrieved by the physician and handed over to basic embryologist to identify and grade oocytes and washed sperms are placed in a embryo toxic tested, sterile, individual single use capsule (invocell) and placed in vaginal cavity using diaphragm, patient goes back to home with some instructions for care, on day 2 patient comes back to the ivf clinic and physician gets the capsule out and hands over to the basic embryologist trained on invocell to identify embryos and grade them, further loading of embryos on et catheter.

Eligibility criteria:
inclusion criteria: * tubal factor without hydrosalpinx * unexplained infertility with unsuccessful attempts in achieving pregnancy through timed intercourse or iui * boarder line male factor infertility * sperm dna fragmentation \< 30% * normal uterine cavity * normal baseline ultrasound with adequate number of primary follicles present * normal fsh and e2 on day 3 * age of the female is \< 35 years old exclusion criteria: * if previous ivf or invo attempts resulted in failed fertilisation * male partner who has difficulty in producing semen sample * very low sperm count, very low percentage of sperm motility and morphology * sperm dna fragmentation \> 30% * age of female patient \> 37 years * borderline or elevated e2 or fsh on day 3 or failed ccct or low blood inhibin levels * poor ovarian response * hydrosalpinx * anatomic difficulties in reaching ovaries for oocyte retrieval * cervical stenosis, making embryo transfer difficult * uterine abnormalities or deformities * obesity
nicotine's effect on cancer stem cell markers in human umbilical cord tissue

Conditions: Umbilical Cord Issue; Nicotine Addiction; Pregnancy Related; Cancer

Summary: the umbilical cord is generally an organ that clinicians and pathologists do not pay sufficient attention to. the absence of significant pathology in the umbilical cords, along with the lack of association between certain placental pathologies and perinatal mortality and morbidity, have led both clinicians and pathologists to inadequately evaluate the placenta and umbilical cord. in our study, i̇nvestigators aimed to perform immunohistochemical and biochemical analysis by comparing two groups, one consisting of women who smoked throughout their pregnancy and the other of those who never smoked, including different markers in accordance with the literature. method: the pregnant women included in the study were categorized according to their smoking status as follows: group i: non-smokers (smoking -) group ii: smokers (smoking +) during pre-pregnancy and throughout the pregnancy in this study, 40 pregnant women who smoked during their pregnancy (between 37 and 42 weeks of gestation) and 37 age- and parity-matched healthy non-smoking pregnant women with full-term births between 37 and 42 weeks of gestation were selected as the control group. umbilical cord samples (2 ml of blood and a 5 cm tissue sample) were collected from both groups without delay and fixed in 10% formalin. the tissue samples were processed for histological analysis with routine hematoxylin and eosin (h\&e) staining following fixation in 10% formalin solution and routine paraffin embedding. i̇nvestigators aimed to examine the presence of oncological factors such as cd44, cd34, cd90, and aldh molecules in the umbilical cord tissue of smokers during pregnancy through immunohistochemistry, and to explore the biochemical relationship of these molecules with their counterparts, cd34, cd44, cd90, and aldh, found in the umbilical cord blood.


Eligibility criteria:
inclusion criteria: * healthy pregnancy under 37 weeks * age range 18-50 * being literate in turkish * not having any additional disease * agreeing to participate in the study exclusion criteria: * high-risk pregnancies (gestational hypertension, preeclampsia, hellp syndrome, chronic hypertension, gestational and pregestational diabetes, cholestasis, intrauterine growth retardation, etc.) * multiple pregnancy * pregnant women under the age of 18 * smoking * medication use (excluding routinely used food supplements during pregnancy) * additional disease (thyroid, renal failure, liver failure, hepatitis, heart disease, connective tissue disease, etc.) * immunosuppressive use * presence of active or chronic infection * presence of active or chronic inflammatory disease * patients who gave birth at an external center or later chose to withdraw from the study * patients who did not have any exclusion criteria at the time of smokers or when blood was drawn for the control group, but who later developed any exclusion criteria. * premature birth of patients included in the control group

Keywords: umblical cord nicotine addiction cd44 cd34 cd90 aldh
optimal evaluation to reduce cardiovascular imaging testing

Conditions: Chronic Coronary Syndrome

Summary: in daily clinical routine, the evaluation of new-onset and stable chest pain (scp) suggestive of chronic coronary syndrome (ccs) remains a challenge for physicians. although coronary computed tomography angiography (ccta) seems to be the first-line cardiac imaging testing (cit) according to the recommendations from current guidelines, the optimal diagnostic strategy to identify low risk patients who may derive minimal benefit from further cit is the cornerstone of clinical management for scp. recently, different diagnostic strategies were provided to effectively defer unnecessary cit, but few studies have prospectively determined the actual effect of applying these strategies in clinical practice. therefore, the operate study was designed to compare the effectiveness and safety of two proposed diagnostic strategies in identification of low risk individual who may derive minimal benefit from ccta among patients with scp suggestive of ccs in a pragmatic randomized controlled trial (rct).

operate trial was an investigator-initiated, multicenter, prospective, ccta-based, 2-arm 1:1 parallel-group, double-blind and pragmatic rct planned to include 800 subjects with scp suggestive of ccs. subjects were assigned randomly to two groups: 1) 2016 national institutes for clinical excellence guidelines-determined diagnostic strategy (nice strategy) and 2) 2019 european society of cardiology guidelines-determined diagnostic strategy (esc strategy) the primary objective of operate trial is to compare the rates of ccta without obstructive cad according to nice and esc strategy. the key secondary objective is to assess whether the two strategies have no significant difference in terms of major adverse cardiac events (mace). the investigators hypothesize that when comparing with nice strategy, esc strategy which sequentially incorporated the esc-ptp model with rf-cl model will decrease the probability of ccta without obstructive cad but not at the expense of safety and cost over a follow-up period of 1 year.

Eligibility criteria:
inclusion criteria 1. scp or equivalenta suggestive of ccs and clinically stability 2. no history of cad (prior myocardial infarction, cr or any cad documented by previous cit) 3. age ≥30 years 4. willing and able to provide informed consent exclusion criteria 1. prior cit within 1 year prior to randomization 2. clinically instability (e.g. cardiogenic shock, acs, severe arrhythmias or nyha iii or iv heart failure) 3. non-sinus rhythm 4. concomitant participation in another clinical trial 5. complex structural heart disease 6. non-cardiac illness with life expectancy \< 2 years 7. allergy to iodinated contrast agent 8. estimated glomerular filtration rate\<60 ml/min/1.73m2 within 90 days 9. body mass index \>35kg/m2 10. expressing a clear preference for undergoing cit or not 11. pregnancy

Keywords: stable chest pain pretest probability coronary computed tomography angiography diagnostic strategy coronary artery disease
a 4-arm efficacy and safety study of rt001 for the treatment of moderate to severe lateral canthal lines in adults

Conditions: Lateral Canthal Lines; Crow's Feet; Facial Wrinkles

Summary: the purpose of this study is to find out if an investigational drug, called rt001 topical gel, is safe and useful in minimizing the wrinkles between the eye and hairline called lateral canthal lines, also known as crow's feet wrinkles.

rt001, a new drug, may be effective for the temporary improvement in the appearance of moderate to severe lateral canthal lines (crow's feet wrinkles) in adults. in this study, researchers want to find out if rt001 is more effective than three comparator groups by examining the effect on the improvement of crow's feet by both the patient and physician.

Eligibility criteria:
inclusion criteria: * written informed consent including authorization to release health information * female or male, 18 to 65 years of age and in good general health * willing and able to follow study instructions and likely to complete all study requirements * moderate to severe lateral canthal lines (crow's feet wrinkles) exclusion criteria: * any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type a, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as lambert-eaton syndrome and myasthenia gravis * muscle weakness or paralysis, particularly in the area receiving study treatment * active disease or irritation at the treatment areas including the eye and the skin * pregnant, nursing, or planning a pregnancy during the study; or is a women of child bearing potential (wocbp) but is not willing to use an effective method of birth control * previous participation in a rt001 clinical study

Keywords: lateral canthal lines crow's feet wrinkles facial wrinkles
influence of an anti-osteoporotic drug on healing after surgical repair of chronic rotator cuff lesions of the shoulder

Conditions: Orthopedics; Traumatology

Summary: this is a prospective, single-center, placebo-controlled, non-comparative, phase ii study to evaluate the influence of an adjuvant, intravenous therapy with zoledronic acid (single dose) on healing after arthroscopic repair of chronic rotator cuff tears. the study including its financial support was approved by the medical director of the general accident insurance institution (auva) , dr. roland frank. hypothesis to prove: adjuvant intravenous therapy with zoledronic acid does improve tendon healing after arthroscopic reconstruction of chronic rotator cuff tears compared to a control group without adjuvant therapy with zoledronic acid.,


Eligibility criteria:
inclusion criteria * age between 50 and 70 years * magnetic resonance imaging verified rotator cuff tear (within 6 month prior to surgery) * rupture size with a maximum diameter of 3 cm * willingness to participate in the study * willingness to participate in a unified physiotherapy with use of a shoulder abduction pad for four weeks postoperativel exclusion criteria: * patients younger than 50 or older than 70 years of age * pregnancy * known allergy to zoledronic acid or other components of the medicinal product * previous fracture of the affected shoulder * previous surgery of the affected shoulder * previous or existing bacterial infection of the affected shoulder * rupture of more than two tendons in the affected shoulder (massive rotator cuff tear) * isolated subscapularis tendon tear * presence of glenohumeral osteoarthritis (hamada type 3 or higher) * diabetes mellitus (fasting glucose ≥ 126 mg/dl, hba1c ≥ zorro version draft1.0/09.05.2022 page 6 of 42 6.5%) * malignant tumor disease * pathological dental status * known disease that interferes with bone metabolism * concomitant diseases that do not permit general anesthesia * previous therapy with anti-osteoporotic drugs (bisphosphonates, denosumab, teriparatide) * epilepsy * claustrophobia * chronic alcohol abuse * drug abuse

Keywords: zoledronic acid chronic rotator cuff tears arthroscopic repair
international travel patterns and health preparations of hematopoietic stem cell transplant recipients at memorial sloan-kettering cancer center

Conditions: Hematopoietic Stem Cell Transplant

Summary: the purpose of this study is to survey patients who underwent hematopoietic stem cell transplant (hsct) to assess if they have traveled or not internationally after transplant. this information will help to improve the understanding of the needs for travel health strategies and interventions to provide healthy and safe travel to hsct patients. the findings of this survey will also be used to develop travel health related interventions for patients living with cancer as well.


Eligibility criteria:
inclusion criteria: * hematopoietic stem cell transplant (hsct) recipients at mskcc from 1/1/2005 to 12/31/2010. * age at hsct ≥ 18 years * permanent mailing address in the united states of america exclusion criteria: * subject unable to fill the questionnaire due to language barriers.

Keywords: international travel cancer patients hsct quality of life questionnaire 11-176
labelled carbon sucrose breath test (13c-sbt) as a marker of environmental enteropathy

Conditions: Glucose-Galactose Malabsorption; Enteropathy; Malnutrition, Child; Intestinal Permeability; Linear Growth Failure

Summary: linear growth failure, a manifestation of chronic undernutrition in early childhood, is a recalcitrant problem in resource constrained settings. the underlying causes of growth failure are multifactorial, but persistent and recurrent infection and inflammation of the gastrointestinal tract and immune activation, a condition commonly referred to as environmental enteropathy, is an important contributor. a highly enriched 13c-sucrose breath test, a measure of sucrase-isomaltase activity, will be evaluated as a non-invasive biomarker of environmental enteropathy, and more specifically of intestinal brush border enzyme activity in 6 resource poor countries (bangladesh, india, jamaica, kenya, peru and zambia) in 100 volunteers aged 12-15 months (total n=600) and evaluated relative to the lactose rhamnose test and linear and ponderal growth over a 3-6 month period following biomarker assessment. field usability will also be assessed.

environmental enteropathy is associated with linear and ponderal growth shortfalls in young children in resource constrained settings. however, the physiological alterations of intestinal function that accompany both the demonstrable evidence of inflammation and architectural changes seen in biopsies from effected children have yet to be elucidated, and this knowledge gap limits the development of effective strategies to optimally manage the condition. furthermore, a limited number of non-invasive assays exist with which to assess the presence of environmental enteropathy in low resource settings. this study aims 1) to determine if sucrose-isomaltase enzyme is altered in children with environmental enteropathy by using a 13c-sucrose breath test 2) to determine if the test is able to be employed in resource limited settings.

Eligibility criteria:
inclusion criteria: all children will be recruited and enrolled through convenience sampling, either at the community level (if the study site has previously censused the community) or through child clinic visits. exclusion criteria: 1. severe acute malnutrition 2. hiv positive 3. weight for height z \>+2 4. known medical illness contributing to growth failure
a registry study assessing pro, dosing patterns, and safety of vunakizumab in patients with general rheumatic diseases.

Conditions: Ankylosing Spondylitis (AS); Psoriatic Arthritis (PsA); Nr-axSpA; Polymyalgia Rheumatica (PMR); Takayasu Arteritis (TAK); Giant Cell Arteritis (GCA); Behcet&#39;s Disease; Enthesitis-related Arthritis

Summary: ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, takayasu arteritis, giant cell arteritis, non-ocular behcet's disease, and enthesitis-related arthritis are common diseases in rheumatology. traditional anti-rheumatic drugs are less effective and have greater side effects than biological agents. at present, there has been no large-scale registration study on rheumatic autoimmune diseases such as spondyloarthritis in china. however, data such as patient characteristics, medication patterns, and patient outcome reports of different rheumatology diseases can often serve as a reference for rheumatology clinicians to reasonably select treatment methods for different patients. therefore, a large-scale registration study is needed to fill the gap in multi-disease registration studies in rheumatology departments in china.


Eligibility criteria:
inclusion criteria: 1. diagnosed with rheumatic autoimmune diseases such as ankylosing spondylitis/radiologically negative axial spondyloarthritis/psoriatic arthritis/polymyalgia rheumatica/takayasu arteritis/giant cell arteritis/ non-ocular behcet's disease/ enthesitis-related arthritis; 2. currently receiving or planning to receive fulvezinib treatment; 3. can follow up according to the doctor's advice; 4. able to understand and sign the informed consent form, understand the purpose of this study, and voluntarily participate in this study. exclusion criteria: 1.investigator believes will prevent the subject from following and completing the study protocol
evaluating dyspnea in autoimmune myasthenia gravis "why am i short of breath?"

Conditions: Myasthenia Gravis; Dyspnea

Summary: individuals with mg (iwmg) experience shortness of breath that may be activity-related, occur at rest and even happen during sleep. dyspnea is a complex, multidimensional and multifactorial symptom involving sensory perception, cognition and emotion. identifying the cause(s) of dyspnea in mg may assist in finding therapeutic strategies, reducing discomfort, improving qol and potentially limiting respiratory deterioration and incidence of mg crisis.

myaresp is a prospective observational, cross-sectional study to evaluate dyspnea in adults with autoimmune myasthenia gravis. study aims include to: * describe the characteristics of dyspnea in iwmg * understand contributing factors and factors associated with dyspnea in iwmg including the relationship between patient-reported dyspnea, disease severity and functional limitations. * determine the most effective tests to identify the causes and contributing factors of dyspnea

Eligibility criteria:
inclusion criteria: * age ≥18 * confirmed diagnosis of autoimmune mg * shortness of breath in daily life: score 1 or 2 on the respiration item on the mg- activities of daily living score * signed consent form * affiliated to or beneficiary of a social security scheme exclusion criteria: * known pregnancy * known respiratory disorder (other than mg) * recent (within past 4 weeks) respiratory infection * current mg crisis or exacerbation (necessitating increase in mg medication \&/or hospital admission) * no dyspnea - score 0 or 3 on the respiration item on the mg- activities of daily living score * severe cognitive impairment/guardianship

Keywords: dyspnea breathlessness respiratory
a study of cariprazine in patients with chronic stable schizophrenia

Conditions: Schizophrenia

Summary: this is an outpatient study to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.


Eligibility criteria:
inclusion criteria: * patients who have completed the double-blind treatment period of the lead-in study rgh-md-16 (nct 00694707) * patients who have responded to double-blind treatment in the lead-in study as defined as ≥ 20% reduction relative to visit 2 (baseline) of the positive and negative syndrome scale (panss) total score and a clinical global impressions-severity (cgi-s) score of ≤ 3. * patients eligible to continue as outpatients based on the opinion of the principal investigator. * patients must have a caregiver to ensure treatment compliance. exclusion criteria: * patients with clinically significant abnormalities on physical examination, laboratory, vital signs, and/or electrocardiogram (ecg).